Claims for Patent: 10,722,516

Summary for Patent: 10,722,516

Title:	Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
Abstract:	The invention provides a new use of landiolol hydrochloride for persistent reduction of the heart rate during the administration period of landiolol hydrochloride in the treatment of a human suffering from tachycardia, tachyarrhythmia or elevated blood pressure, wherein landiolol hydrochloride is administered at a constant dose of more than 5 μg/kg/min, specifically of at least 10 μg/kg/min for a period of at least 2 hours and wherein the heart rate and/or blood pressure of said patient are persistently reduced during the administration period compared to the heart rate and/or blood pressure before treatment and no overshooting effect occurs after termination of said administration.
Inventor(s):	Günther Krumpl
Assignee:	AOP Orphan Pharmaceuticals AG
Application Number:	US14/787,217
Patent Claims:	1. A method of reducing the heart rate of a subject suffering from supraventricular tachycardia, wherein the method consists of the step of administering landiolol hydrochloride parenterally to the subject at a constant dose of more than 20 μg/kg/min for a period of from 2 to 20 hours, wherein the dose is not higher than 40 μg/kg/min. 2. The method of claim 1, wherein the constant dose of landiolol hydrochloride is at least 25 μg/kg/min, at least 30 μg/kg/min, or at least 35 μg/kg/min. 3. The method of claim 1, wherein landiolol hydrochloride is administered for at least 4 hours, for at least 6 hours, or for at least 12 hours. 4. The method of claim 1, wherein the heart rate of the subject is reduced by at least 5%, or by between 10% and 50%, compared to the heart rate of the subject before the administration of landiolol hydrochloride. 5. The method of claim 1, wherein no overshoot effect occurs after termination of the administration of landiolol hydrochloride to the subject. 6. The method of claim 1, wherein the subject's heart reaches a normal rate within 5 to 20 minutes after termination of administration of landiolol hydrochloride to the subject. 7. The method of claim 1, wherein said landiolol hydrochloride is at a concentration of about 1 mg/mL to 30 mg/mL, or at a concentration of about 5 to 15 mg/mL. 8. The method of claim 1, wherein said landiolol hydrochloride is provided as a solution. 9. The method of claim 8, wherein said solution has a pH of up to 6.5. 10. The method of claim 8, wherein said solution is administered by a route selected from the group consisting of subcutaneous administration, intravenous administration, intraarterial administration, and intracoronary administration. 11. The method of claim 8, wherein said solution is local tissue tolerant at the infusion site, thereby preventing local venous irritation or skin necrosis at the infusion site. 12. The method of claim 1, wherein said subject is suffering from intoxication due to a positive intotropic drug or a sympathomimetic drug. 13. The method of claim 8, wherein the solution is prepared by reconstituting a lyophilized powder comprising landiolol hydrochloride. 14. The method of claim 10, wherein the solution of landiolol hydrochloride is administered as a continuous intravenous infusion. 15. The method of claim 1, wherein said landiolol hydrochloride is provided for a period of up to 4 hours.